Reliance Capital Valuation
Is RELCAPITAL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RELCAPITAL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: RELCAPITAL (₹12.35) is trading below our estimate of fair value (₹1331.52)
Significantly Below Fair Value: RELCAPITAL is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RELCAPITAL?
Key metric: As RELCAPITAL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is RELCAPITAL's PS Ratio? | |
|---|---|
| PS Ratio | 0.02x |
| Sales | ₹181.81b |
| Market Cap | ₹3.12b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1x |
| Enterprise Value/EBITDA | -16.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does RELCAPITAL's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.6x | ||
AMAT Al Madina Insurance Company SAOG | 0.7x | n/a | ر.ع13.8m |
PICO Palestine Insurance | 0.6x | n/a | US$31.5m |
BHASS BH Assurance | 0.8x | 6.1% | د.ت133.0m |
ASNIC Al-Sagr National Insurance Company (PSC) | 0.3x | n/a | د.إ151.1m |
RELCAPITAL Reliance Capital | 0.02x | n/a | ₹3.1b |
Price-To-Sales vs Peers: RELCAPITAL is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (1.5x).
Price to Sales Ratio vs Industry
How does RELCAPITAL's PS Ratio compare vs other companies in the Asian Insurance Industry?
| 20 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 0.9x | 9.1% | |
RELCAPITAL Reliance Capital | 0.02x | n/a | US$37.57m |
| 20 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 0.9x | 8.0% | |
RELCAPITAL Reliance Capital | 0.02x | n/a | US$37.57m |
Price-To-Sales vs Industry: RELCAPITAL is good value based on its Price-To-Sales Ratio (0x) compared to the Asian Insurance industry average (0.9x).
Price to Sales Ratio vs Fair Ratio
What is RELCAPITAL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.02x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate RELCAPITAL's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Star Health and Allied Insurance
₹270.1b
Provides health insurance products in India.
543412
₹459.90
7D
-3.1%
1Y
-19.5%
General Insurance Corporation of India
₹664.7b
Provides reinsurance services in India and internationally.
540755
₹378.40
7D
6.8%
1Y
23.0%
Star Health and Allied Insurance
₹270.1b
Provides health insurance products in India.
STARHEALTH
₹459.70
7D
-3.2%
1Y
-19.4%